H.C. Wainwright analyst Sean Lee CFA maintained a Buy rating on Monopar Therapeutics Inc (MNPR – Research Report) today and set a price target of $40.00.
Sean Lee CFA has given his Buy rating due to a combination of factors related to Monopar Therapeutics Inc’s strategic advancements and financial projections. The company is on track to submit a New Drug Application (NDA) for ALXN1840, targeting Wilson’s disease, by early 2026. This submission is a significant milestone, as the potential market for ALXN1840 in the U.S. alone is estimated to reach $420 million, with expectations of risk-adjusted revenues starting at $5 million in 2026 and growing substantially thereafter.
Additionally, Monopar’s progress with MNPR-101, an antibody-drug conjugate for treating advanced solid tumors, further supports the Buy rating. The ongoing Phase 1 study of MNPR-101-Lu has shown promising initial patient enrollment, with results anticipated in late 2025 or early 2026. The valuation of Monopar’s stock is supported by a risk-adjusted net present value analysis, leading to a 12-month price target of $40.00 per share. This valuation considers projected future revenues, royalties, and the company’s current cash reserves, while also acknowledging potential risks in clinical, regulatory, commercial, financial, and intellectual property areas.
In another report released yesterday, Citi also maintained a Buy rating on the stock with a $40.00 price target.